Explore the Agenda
Pre-Conference Day
Monday, March 16
Day One
Tuesday, March 17
Day Two
Wednesday, March 18
8:00 am Check In, Coffee & Light Breakfast
8:55 am Chair’s Opening Remarks
Optimizing CKD Development For Paediatric, Young Adult & Congenital Populations
9:00 am Uncovering Congenital Kidney Disease Within Existing CKD Trials to Access a Cleaner Young Adult Population & Inform Endpoints Beyond Proteinuria
- Characterizing congenital kidney disease (CAKUT) as a young adult CKD population with fewer confounding comorbidities and a decades-long treatment window
- Identifying patients already enrolled in adult CKD trials through a single case report form field and a practical ICD-10 code set
- Generating adult evidence to support paediatric extrapolation and earlier paediatric planning
- Exploring why early congenital kidney disease, before heavy proteinuria, offers a model for endpoints beyond proteinuria
9:30 am Session Reserved for Antaros
10:00 am Designing for Paediatric & Young Adult CKD Earlier to Meet Regulatory Expectations & Access Cleaner Development Populations (e.g. FSGS, Alport Syndrome)
- Integrating paediatric development planning earlier rather than treating it as a postapproval requirement
- Recognizing young adults with CKD who may carry fewer confounding comorbidities and background medications
- Adapting endpoints and trial designs for younger and more slowly progressing populations
10:30 am Morning Break & Refreshments
Discovery & Preclinical
Overcoming Renal Delivery Barriers to Enable Precision RNA Therapeutics in the Kidneys
11:30 am Advancing Kidney-Targeted RNA Therapies to Overcome Delivery Barriers & Unlock New Renal Biology
- Harnessing endogenous kidney recycling receptors such as megalin to deliver ligand-siRNA conjugates selectively to proximal tubule epithelial cells and achieve durable gene silencing in the kidney
- Targeting solute carrier proteins and other disease-modifying genes within specific renal cell populations to expand the range of biology accessible to oligonucleotide therapeutics
- Extending receptor-mediated delivery beyond the proximal tubule into additional kidney cell types and diseases to build a broader platform for precision RNA medicines in renal and systemic disease
12:00 pm Unlocking the Kidney for RNA Medicines: Targeted Delivery to Enable Next-Generation Renal Therapeutics
- Developing kidney-targeted delivery for therapeutically relevant renal cells
- Overcoming biological barriers that limit efficacy and safety of systemic therapies
- Matching modality selection to target biology and disease indication
Clinical & Regulatory
Advancing Next-Generation CKD Therapeutics Through Gene Therapy & Residual Disease Biology
11:30 am Clinical Development of AAV Based Gene Therapies for Glomerular Diseases
- Expected side effects of AAV-based gene therapies, and mitigation strategies
- Operationalizing gene therapies in nephrology
- Current and coming clinical gene therapies targeting glomerular diseases
12:00 pm Targeting Residual Risk Beyond SGLT2s & GLP-1s to Discover the Mechanisms Driving Continued CKD Progression
- Profiling molecular pathways that remain active after current standard-of-care treatment
- Identifying immune, inflammatory and fibrotic mechanisms contributing to persistent progression
- Translating residual disease biology into differentiated therapeutic hypotheses
12:30 pm Lunch & Networking Break
Precision Targeting & Anti-Fibrotic Strategies To Protect Kidney Function & Limit Tissue Damage
1:30 pm Targeting Specific Kidney Cell Types to Deliver Potent Therapies Where They Are Needed & Minimize Off-Target Exposure
- Matching glomerular, tubular, endothelial and podocyte biology with appropriate targeting strategies
- Comparing passive renal accumulation with active cellspecific targeting
- Optimizing therapeutic index by limiting unnecessary systemic exposure
2:00 pm Targeting Fibrotic Remodeling After Kidney Transplantation to Preserve Graft Function & Extend Organ Survival
- Defining fibrosis as a distinct driver of progressive graft dysfunction following kidney transplantation to identify patients who continue to deteriorate despite control of immune-mediated rejection
- Targeting DDR1-driven collagen sensing and maladaptive extracellular matrix remodelling to interrupt the self-sustaining fibrotic cycle while preserving the physiological repair required for normal tissue healing
- Combining protocol biopsies, molecular patient selection and early target-engagement biomarkers to translate anti-fibrotic biology into a personalised clinical development strategy and demonstrate graft preservation earlier
Connecting Early Clinical Development with the Evolving CKD Standard of Care
1:30 pm Designing a Clinical Development Path for Anti- Fibrotic Therapy in CKD to Establish Early Proof-of- Concept & De-Risk Phase II
- Advancing MTX-439 from healthy-volunteer Phase I into kidney disease patients to translate a novel anti-fibrotic mechanism into a clinically relevant CKD development program and define the exposure required for therapeutic activity
- Prioritizing diabetic kidney disease and other populations with persistent fibrotic progression despite treatment of the underlying disease to target residual kidney damage where anti-fibrotic intervention could help delay dialysis or transplantation
- Integrating SMOC2, fibrosis biomarkers and non-proteinuric development endpoints into Phase II design to identify patients most likely to benefit, establish proof-of-concept earlier and address the uncertainty around how to develop therapies that do not primarily act at the glomerulus
2:00 pm Translating Expanding Therapeutic Choice into Practical CKD Treatment Algorithms to Guide the Next Standard of Care
- Determining which treatment to initiate, layer or switch according to disease mechanism and stage
- Integrating efficacy, safety, cardiovascular risk, patient preference and access into decision-making
- Identifying the evidence still required before precision sequencing becomes routine clinical practice
2:30 pm Afternoon Break & Refreshments
Translating Mechanistic Insight & Therapeutic Choice Into The Next Standard Of CKD Care
3:00 pm Learning Across Proteinuric Kidney Diseases to Translate Shared Mechanisms into Disease-Modifying Therapies
- Identifying shared biological drivers across FSGS, IgAN, membranous nephropathy and Alport syndrome to move beyond symptom control and develop therapies capable of modifying underlying disease biology
- Targeting podocyte injury, suPAR/uPAR signaling and cytoskeletal dysfunction to preserve glomerular filtration and kidney function across genetically and mechanistically diverse proteinuric diseases
- Using cross-indication clinical and biomarker evidence to determine where common mechanisms can support broader development strategies while preserving disease-specific patient selection and endpoints
3:30 pm Sequencing & Combining CKD Therapies to Turn Expanding Treatment Choice into Better Patient Outcomes
- Determining which mechanism should be introduced first for different biological and clinical phenotypes
- Evaluating when combination or sequential therapy offers advantage over monotherapy
- Balancing efficacy, safety, pill burden, cost and treatment stage when constructing future care pathways
- Shared decision making between the clinician and patient